Targeted (Intra)arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab Paclitaxel following Induction with Sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC)
Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for Locally Advanced Pancreatic Cancer (TIGeR-PaC)
Sponsor: RenovoRx
Enrolling: Male and Female Patients
IRB Number: AAAT5973
U.S. Govt. ID: NCT03257033
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: One of the major reasons given for the failure of pancreatic cancer chemotherapy to work effectively in preventing the growth of the cancer is because when given through a vein that goes throughout the body, the chemotherapy does not properly reach the tumor to produce its effect. The purpose of this research study is to find out whether using a newer method of targeted local delivery of the chemotherapy directly into an artery close to the pancreas tumor after treatment with standard chemotherapy that is delivered by vein is more effective at preventing the tumor from growing as compared with just receiving standard chemotherapy into a vein that goes throughout the body. This study will compare how IA and IV medication affects the time that patients survive and their quality of life.
Susan Bates, MD
Do You Qualify?
Are you age 18 or older? Yes No
Have you been diagnosed with pancreatic cancer? Yes No
Do you have HIV or hepatitis? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator